Drug Database · Clinicians

Indocyanine green

Brands (1) VerdyeShow all

US brand (reference label): Zyogreen; not a Philippine-registered brand.

Diagnostic Dye (Dyes) US FDA class
Diagnostic agent (radiopaque and non-radioactive) PH FDA category

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b2de0c9a-0065-4f2c-9983-add39525f3a3, version date July 16, 2026 (Zyogreen · Sagent Pharmaceuticals). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries…
  • Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and 6 years of age and older
  • Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer
  • Ophthalmic angiography in adults and pediatric patients
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE ZYOGREEN is an optical imaging agent indicated for: Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients (1.1) Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and 6 years of age and older (1.2) Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer (1.3) Ophthalmic angiography in adults and pediatric patients (1.4) 1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion ZYOGREEN is indicated for fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures in adults and pediatric patients. 1.2 Visualization of Extrahepatic Biliary Ducts ZYOGREEN is indicated for fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and 6 years of age and older. 1.3 Lymphatic Mapping of Cervical and Uterine Cancer ZYOGREEN is indicated for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer for which this procedure is a component of intraoperative management. 1.4 Ophthalmic Angiography ZYOGREEN is indicated for use in ophthalmic angiography in adults and pediatric patients.

Contraindications

4 CONTRAINDICATIONS ZYOGREEN is contraindicated in patients with a history of hypersensitivity to indocyanine green. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)]. Hypersensitivity to indocyanine green (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Visualization of vessels, blood flow and tissue perfusion Pediatric patients less than 1 month of age: 0.15 mg/kg Adults and pediatric patients 1 month of age and older: 1.25 mg to 5 mg by intravenous injection (2.2)
  • Extremity perfusion visualization through the skin Pediatric patients less than 1 month of age: 0.15 mg/kg Pediatric patients 1 month of age and older: 1.25 mg to 5 mg Adults: 3.75 mg to 10 mg by intravenous injection (2.2)
  • Visualization of extrahepatic biliary ducts Pediatric patients from birth to less than 1 year of age: 0.1 mg/kg (not to exceed 2.5 mg) 12 to 24 hours prior to surgery Adults and pediatric patients 6 years of age and older: 2.5 mg by intravenous injection at least 45 minutes prior to surgery (2.3)
  • Lymphatic mapping of cervical and uterine cancer in adults 5 mg interstitially as four 1.25 mg injections. See Full Prescribing Information for injection techniques. (2.4)
  • Ophthalmic Angiography in adults and pediatric patients: doses up to 40 mg by intravenous injection. (2.5)
  • The total dose must not exceed 2 mg/kg for all patients.
2.1 Important Administration Instructions

2.1 Important Administration Instructions ZYOGREEN is a ready-to-use solution, provided in ampules at a concentration of 2.5 mg per mL. Use immediately after opening ampule. Withdraw the contents of the ampule through a 5 micrometer or smaller straw/filter needle to ensure that the withdrawn solution contains no particulates.

Visually inspect the withdrawn solution for particulate matter and discoloration prior to administration. Each ampule of ZYOGREEN is for a single dose. Discard any unused portion.

2.2 Recommended Dose, Administration and Imaging for Visualization of Vessels, Blood Flow and…

2.2 Recommended Dose, Administration and Imaging for Visualization of Vessels, Blood Flow and Tissue Perfusion Dosing Administer the recommended initial dose of ZYOGREEN as a single intravenous injection. The recommended initial dose is based on patient age as shown in Table 1. Additional doses may be administered to obtain imaging sequences during the procedure.

The maximum total dose for any patient, including all initial and additional doses combined, must not exceed 2 mg/kg. Table 1. Recommended Dose of ZYOGREEN for Visualization of Vessels, Blood Flow and Tissue Perfusion by Age * Dose based on actual body weight Imaging Patient Age Recommended Dose Visualization of vessels, blood flow and tissue perfusion (single imaging sequence) Pediatric patients from birth to less than 1 month of age 0.15 mg/kg * Pediatric patients 1 month of age and older 1.25 mg to 5 mg Adults Extremity perfusion visualization through the skin (single imaging sequence) Pediatric patients from birth to less than 1 month of age 0.15 mg/kg * Pediatric patients 1 month of age and older 1.25 mg to 5 mg Adults 3.75 mg to 10 mg Administration Prior to the imaging procedure, draw the desired dose of ZYOGREEN into a syringe.

For adults, prepare 10 mL of 0.9% Sodium Chloride Injection in a separate syringe for flushing. For pediatric patients, adjust the amount and type of flush for the individual patient to avoid volume and sodium overload. Administer via a central or peripheral venous line using a three-way stopcock. Inject ZYOGREEN as a tight bolus.

Immediately switch the access on the stopcock and inject the prepared flush. Imaging Instructions Use ZYOGREEN with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of vessels, blood flow and tissue perfusion. A fluorescence response should be visible in blood vessels within 5 seconds to 15 seconds after injection.

2.3 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary…

2.3 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary Ducts Dosing and Administration Administer the recommended dose of ZYOGREEN as a single intravenous injection. The initial dose and timing of administration are based on patient age as shown in Table 2. Additional doses may be administered to obtain imaging sequences during the procedure.

The maximum total dose for any patient, including all initial and additional doses combined, must not exceed 2 mg/kg. Table 2: Recommended Dose of ZYOGREEN for Visualization of Extrahepatic Biliary Ducts by Age * Dose based on actual body weight Patient Age Recommended Dose Timing of Administration Pediatric patients from birth to less than 1 year of age 0.1 mg/kg * (Do not exceed 2.5 mg) Administer 12 hours to 24 hours prior to surgery Pediatric patients from 1 to less than 6 years of age Not indicated Not applicable Pediatric patients 6 years of age and older 2.5 mg Administer at least 45 minutes prior to surgery Adults Imaging Instructions Use ZYOGREEN with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of extrahepatic biliary ducts.

For patients 6 years of age and older, fluorescence is visible in the biliary tree within 45 minutes after injection. For patients less than 1 year of age, fluorescence is visible in the biliary tree between 12 hours and 24 hours after injection.

2.4 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and…

2.4 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and Uterine Cancer Dosing and Administration The recommended dose of ZYOGREEN for lymphatic mapping of cervical and uterine cancer in adults is 5 mg. Administer this dose interstitially as four separate 1.25 mg injections into the cervix, with each injection consisting of a 0.5 mL volume of the 2.5 mg/mL solution.

The injections should be given at the 3 o'clock and the 9 o'clock positions of the cervix. At each of these two positions, one superficial injection (1 mm to 3 mm depth) and one deep injection (1 cm to 3 cm depth) are required to complete the dosing. Imaging Instructions Use ZYOGREEN with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping of cervical and uterine cancer.

Fluorescent lymphatic vessels and lymph nodes should begin to be visible within 1 minute after injection.

2.5 Recommended Dose and Administration for Ophthalmic Angiography

2.5 Recommended Dose and Administration for Ophthalmic Angiography Administer doses up to 40 mg of ZYOGREEN intravenously for ophthalmic angiography in adult and pediatric patients. The specific dose should be determined based on the imaging equipment and technique being used. The total dose must not exceed 2 mg/kg. For adults, administer a 5 mL bolus of 0.9% Sodium Chloride Injection immediately following the injection.

For pediatric patients, adjust the amount and type of flush solution for the individual patient to avoid volume and sodium overload. The antecubital vein can be used for ZYOGREEN administration.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Use in Pediatric Patients for Visualization of Vessels, Blood Flow and Tissue Perfusion The safety and effectiveness of ZYOGREEN for fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures have been established in pediatric patients. Use of ZYOGREEN for this indication in pediatric patients is supported by evidence from clinical trials in adults and published studies that demonstrated the utility of indocyanine green for blood vessel evaluation and assessment of tissue perfusion in 59 pediatric patients, including 6 neonates, during surgeries within the indicated surgical categories.

Use in Pediatric Patients for Visualization of Extrahepatic Biliary Ducts The safety and effectiveness of ZYOGREEN for fluorescence imaging of extrahepatic biliary ducts have been established in pediatric patients from birth to less than 1 year of age and in those 6 years of age and older. Use of ZYOGREEN for this indication in these age groups is supported by evidence from clinical trials in adults and from the following published studies in pediatric patients.

For patients less than 1 year of age, supporting publications included two prospective observational studies and one retrospective case series evaluating a total of 34 pediatric patients (age range: 2 to 119 days) with jaundice undergoing Kasai portoenterostomy who received indocyanine green for fluorescence imaging of biliary structures. For patients 6 years of age and older, a supporting publication consisted of a prospective, single institution case series in 31 pediatric patients (age range: 6 to 18 years) undergoing cholangiography with indocyanine green during laparoscopic cholecystectomy.

The safety and effectiveness of ZYOGREEN have not been established for fluorescence imaging of extrahepatic biliary ducts in pediatric patients 1 year to less than 6 years of age. Use in Pediatric Patients for Ophthalmic Angiography ZYOGREEN is indicated for ophthalmic angiography in pediatric patients. Use in Pediatric Patients for Lymphatic Mapping of Cervical and Uterine Cancer The safety and effectiveness of ZYOGREEN for fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping for cervical and uterine cancer have not been established in pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects in clinical studies of indocyanine green for visualization of vessels, blood flow and tissue perfusion, 7% were 65 and over, while 1% were 75 and over. Of the total number of subjects in clinical studies of indocyanine green for visualization of lymph nodes and lymphatic vessels during lymphatic mapping of cervical and uterine cancer, 9% were 65 and over, while 2% were 75 and over.

No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between elderly and younger patients. Clinical studies of indocyanine green for visualization of extrahepatic biliary ducts did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Administration

2.1 Important Administration Instructions ZYOGREEN is a ready-to-use solution, provided in ampules at a concentration of 2.5 mg per mL. Use immediately after opening ampule. Withdraw the contents of the ampule through a 5 micrometer or smaller straw/filter needle to ensure that the withdrawn solution contains no particulates. Visually inspect the withdrawn solution for particulate matter and discoloration prior to administration. Each ampule of ZYOGREEN is for a single dose. Discard any unused portion.

2.2 Recommended Dose, Administration and Imaging for Visualization of Vessels, Blood Flow and Tissue Perfusion Dosing Administer the recommended initial dose of ZYOGREEN as a single intravenous injection. The recommended initial dose is based on patient age as shown in Table 1 . Additional doses may be administered to obtain imaging sequences during the procedure. The maximum total dose for any patient, including all initial and additional doses combined, must not exceed 2 mg/kg. Table 1. Recommended Dose of ZYOGREEN for Visualization of Vessels, Blood Flow and Tissue Perfusion by Age * Dose based on actual body weight Imaging Patient Age Recommended Dose Visualization of vessels, blood flow and tissue perfusion (single imaging sequence) Pediatric patients from birth to less than 1 month of age 0.15 mg/kg * Pediatric patients 1 month of age and older 1.25 mg to 5 mg Adults Extremity perfusion visualization through the skin (single imaging sequence) Pediatric patients from birth to less than 1 month of age 0.15 mg/kg * Pediatric patients 1 month of age and older 1.25 mg to 5 mg Adults 3.75 mg to 10 mg Administration Prior to the imaging procedure, draw the desired dose of ZYOGREEN into a syringe. For adults, prepare 10 mL of 0.9% Sodium Chloride Injection in a separate syringe for flushing. For pediatric patients, adjust the amount and type of flush for the individual patient to avoid volume and sodium overload. Administer via a central or peripheral venous line using a three-way stopcock. Inject ZYOGREEN as a tight bolus. Immediately switch the access on the stopcock and inject the prepared flush. Imaging Instructions Use ZYOGREEN with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of vessels, blood flow and tissue perfusion. A fluorescence response should be visible in blood vessels within 5 seconds to 15 seconds after injection.

2.3 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary Ducts Dosing and Administration Administer the recommended dose of ZYOGREEN as a single intravenous injection. The initial dose and timing of administration are based on patient age as shown in Table 2 . Additional doses may be administered to obtain imaging sequences during the procedure. The maximum total dose for any patient, including all initial and additional doses combined, must not exceed 2 mg/kg. Table 2: Recommended Dose of ZYOGREEN for Visualization of Extrahepatic Biliary Ducts by Age * Dose based on actual body weight Patient Age Recommended Dose Timing of Administration Pediatric patients from birth to less than 1 year of age 0.1 mg/kg * (Do not exceed 2.5 mg) Administer 12 hours to 24 hours prior to surgery Pediatric patients from 1 to less than 6 years of age Not indicated Not applicable Pediatric patients 6 years of age and older 2.5 mg Administer at least 45 minutes prior to surgery Adults Imaging Instructions Use ZYOGREEN with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of extrahepatic biliary ducts. For patients 6 years of age and older, fluorescence is visible in the biliary tree within 45 minutes after injection. For patients less than 1 year of age, fluorescence is visible in the biliary tree between 12 hours and 24 hours after injection.

2.4 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and Uterine Cancer Dosing and Administration The recommended dose of ZYOGREEN for lymphatic mapping of cervical and uterine cancer in adults is 5 mg. Administer this dose interstitially as four separate 1.25 mg injections into the cervix, with each injection consisting of a 0.5 mL volume of the 2.5 mg/mL solution. The injections should be given at the 3 o'clock and the 9 o'clock positions of the cervix. At each of these two positions, one superficial injection (1 mm to 3 mm depth) and one deep injection (1 cm to 3 cm depth) are required to complete the dosing. Imaging Instructions Use ZYOGREEN with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping of cervical and uterine cancer. Fluorescent lymphatic vessels and lymph nodes should begin to be visible within 1 minute after injection.

2.5 Recommended Dose and Administration for Ophthalmic Angiography Administer doses up to 40 mg of ZYOGREEN intravenously for ophthalmic angiography in adult and pediatric patients. The specific dose should be determined based on the imaging equipment and technique being used. The total dose must not exceed 2 mg/kg. For adults, administer a 5 mL bolus of 0.9% Sodium Chloride Injection immediately following the injection. For pediatric patients, adjust the amount and type of flush solution for the individual patient to avoid volume and sodium overload. The antecubital vein can be used for ZYOGREEN administration.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for i.v.injection: 25 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Indocyanine green as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Indocyanine green
Package insert
VerdyeIndocyanine Green
25 mg Lyophilized Powder for I.V.InjectionPh. Eur. Type 1 amber glass vial with grey bromobutyl stopper and aluminum overseal with flip-off polypropylene cap (Box of 5's)
Rx
Patheon Italia S.P.A.Italy
Transmedic Philippines, Inc.
DR-XY49595
Dec 4, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: 25 mg per 10 mL (2.5 mg per mL) of indocyanine green as a deep emerald-green ready-to-use solution in a single-dose ampule. Injection: 25 mg per 10 mL (2.5 mg per mL) of indocyanine green as a ready-to-use solution in a single-dose ampule (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label

Hypersensitivity reactions: Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor patients. (5.1)

5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Hypersensitivity reactions including anaphylaxis, urticaria, and deaths due to anaphylaxis have been reported following intravenous administration of indocyanine green, the active ingredient in ZYOGREEN [see Adverse Reactions (6)]. ZYOGREEN is contraindicated in patients with a history of hypersensitivity to indocyanine green [see Contraindications (4)].

Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

5.2 Interference with Thyroid Radioactive Iodine Uptake Studies Because

5.2 Interference with Thyroid Radioactive Iodine Uptake Studies Because ZYOGREEN contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration [see Drug Interactions (7)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Interference with Thyroid Radioactive Iodine Uptake Studies: Do not perform radioactive iodine uptake studies for at least one week following the use of ZYOGREEN. (7) Interference with Thyroid Radioactive Iodine Uptake Studies Because ZYOGREEN contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of ZYOGREEN.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)]. The following adverse reactions have been identified during post-approval use of indocyanine green, the active ingredient in ZYOGREEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Anaphylaxis, urticaria The most common adverse reactions reported are anaphylaxis and urticaria. (6) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1–800-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of ZYOGREEN in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Mechanism of action

12.1 Mechanism of Action When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor.

These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and macro- vasculature, blood flow and tissue perfusion, the extrahepatic biliary ducts, and for lymphatic mapping of lymph nodes and lymphatic vessels.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics There is no pharmacodynamic data.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Distribution Following intravenous injection, indocyanine green binds to plasma proteins (98%) and is largely confined to the intravascular compartment. Indocyanine green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebrospinal uptake of the dye.

After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin. Following interstitial injection, indocyanine green binds to proteins in lymph fluid and the interstitial space, is taken up by the lymphatic vessels, and drains to the lymph nodes.

Since excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature, ZYOGREEN is useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera. Elimination Indocyanine green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Zyogreen · Sagent Pharmaceuticals [US FDA-approved label, version 2, July 16, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2de0c9a-0065-4f2c-9983-add39525f3a3
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .